CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 84,496 enrolled
Drug / intervention
VACCINE: placebo +1 morebiological
Likely dose
VACCINE: placebo 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00744263
NCT00744263Phase 4Completed
CompareCT.gov

A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

Pfizer·interventional·Posted Aug 29, 2008·Updated Oct 6, 2014

In Brief

A Phase 4 clinical trial evaluating VACCINE: placebo and VACCINE: 13-valent pneumococcal conjugate vaccine for Pneumonia, Pneumococcal and 2 related conditions. Completed, enrolled 84,496 participants across 159 sites.

Detailed Summary

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
CountriesNetherlands
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 29, 2008
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.8 years ago

Interventions

VACCINE: placebobiological

0.5 mL, single intra-muscular injection

VACCINE: 13-valent pneumococcal conjugate vaccinebiological

0.5 mL, single intra-muscular injection